Covidien Completes Pharma Spinoff, Hears From Tyco On Tax Matter

Covidien is now a $9.9 billion, pure-play medical device and supplies company. Separately, the firm could be liable for more than $1 billion in back taxes due to an IRS audit of its former parent, Tyco, though the case is expected to take years to play out in court.

More from Archive

More from Medtech Insight